Table 4 Clinico-pathological features associated with intraprostatic FDG uptake

Clinical T stage*

cT1

12 (48.0)

6 (26.1)

0.042

12 (50.0)

6 (27.3)

0.13

cT2

10 (40.0)

6 (26.1)

9 (37.5)

7 (31.8)

cT3

3 (12.0)

8 (34.8)

3 (12.5)

7 (31.8)

cT4

0 (0.0)

3 (13.0)

0 (0.0)

2 (9.1)

Pretreatment PSA (ng/ml)

<10.0

23 (76.7)

13 (54.2)

0.21

23 (79.3)

12 (52.2)

0.12

10.0-19.9

5 (16.7)

7 (29.2)

4 (13.8)

7 (30.4)

≥20.0

2 (6.7)

4 (16.7)

2 (6.9)

4 (17.4)

Pathological T stage*

pT2

14 (53.8)

5 (38.5)

0.28

14 (58.3)

5 (35.7)

0.17

pT3

12 (46.2)

7 (53.8)

10 (41.7)

8 (57.1)

pT4

0 (0.0)

1 (7.7)

0 (0.0)

1 (7.1)

Pathological N stage*

pN0

21 (80.8)

9 (60.0)

0.15

21 (84.0)

9 (60.0)

0.090

pN1

5 (19.2)

6 (40.0)

4 (16.0)

6 (40.0)

Gleason score ^†

6

3 (11.5)

0 (0.0)

0.002

3 (12.5)

0 (0.0)

0.029

7

19 (73.1)

4 (30.8)

17 (70.8)

6 (42.9)

8

4 (15.4)

5 (38.5)

4 (16.7)

5 (35.7)

9

0 (0.0)

4 (30.8)

0 (0.0)

3 (21.4)

Gleason pattern ^†

3 + 3

2 (7.7)

0 (0.0)

0.009

2 (8.3)

0 (0.0)

0.062

3 + 4

8 (30.8)

0 (0.0)

7 (29.2)

1 (7.1)

3 + 5

1 (3.8)

0 (0.0)

1 (4.2)

0 (0.0)

4 + 3

12 (46.2)

4 (30.8)

11 (45.8)

5 (35.7)

4 + 4

3 (11.5)

5 (38.5)

3 (12.5)

5 (35.7)

4 + 5

0 (0.0)

3 (23.1)

0 (0.0)

2 (14.3)

5 + 4

0 (0.0)

1 (7.7)

0 (0.0)

1 (7.1)

Intraprostatic cancer extent

0-9%

8 (30.8)

0 (0.0)

0.027

8 (33.3)

0 (0.0)

0.046

10-49%

15 (57.7)

7 (58.3)

13 (54.2)

9 (69.2)

≥50%

3 (11.5)

5 (41.7)

3 (12.5)

4 (30.8)

Margins

Negative

15 (57.7)

8 (61.5)

0.82

15 (62.5)

8 (57.1)

0.74

Positive

11 (42.3)

5 (38.5)

9 (37.5)

6 (42.9)

Extracapsular extension

No

15 (57.7)

6 (46.2)

0.50

15 (62.5)

6 (42.9)

0.24

Yes

11 (42.3)

7 (53.8)

9 (37.5)

8 (57.1)

SV invasion

No

20 (76.9)

8 (61.5)

0.31

19 (79.2)

8 (57.1)

0.15

Yes

6 (23.1)

5 (38.5)

5 (20.8)

6 (42.9)